U.S. License Holder:
Astrazeneca AB
Date of License:
July-17-2023
Last Update:
Dec-15-2024
FDA-Approved Indications
BEYFORTUS (nirsevimab-alip) is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in:
Neonates and infants born during or entering their first RSV season;
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.